CD86 and type 1 diabetes mellitus: Treatment of NOD mice with nanoparticles (NPs) containing short antisense primary transcripts of the costimulatory molecules CD40, CD80, and CD86 has been shown to downregulate targeted receptors, induce a tolerogenic phenotype in DC populations, and prevent and/or reverse T1D [133].